Edition:
United States

Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

62.55EUR
9:53am EST
Change (% chg)

€0.74 (+1.20%)
Prev Close
€61.81
Open
€62.31
Day's High
€63.76
Day's Low
€62.08
Volume
661
Avg. Vol
1,548
52-wk High
€79.74
52-wk Low
€59.00

Latest Key Developments (Source: Significant Developments)

U.S. FDA approves Itrafungol for treating ringworm in cats
Monday, 14 Nov 2016 11:45am EST 

U.S. FDA : U.S. FDA recommends veterinarians prescribe itrafungol, instead of itraconazole compounded from bulk drug substances .U.S. FDA approves Itrafungol, a new animal drug for treating ringworm in cats.  Full Article

Eli Lilly and Co sets quarterly dividend of $0.51/share
Monday, 17 Oct 2016 02:30pm EDT 

Eli Lilly And Co :Sets quarterly dividend of $0.51 per share.  Full Article

EMA recommends approval of three new cancer treatments
Friday, 16 Sep 2016 07:31am EDT 

European Medicines Agency : Recommendations for September 2016 . Recommends approval of Eli Lilly and Boehringer Ingelheim's Glyxambi for treatment of type 2 diabetes . Recommends approval of Pfizer Inc’S palbociclib to treat breast cancer . Recommends conditional approval of Eli Lilly’s olaratumab to treat soft tissue sarcoma . Recommends approval of Amgen's etelcalcetide to treat secondary hyperparathyroidism in patients with chronic kidney disease .Recommends conditional approval of Takeda Pharmaceutical Co Ltd's Ninlaro (ixazomib) to treat multiple myeloma.  Full Article

Macrocure says appointed Douglas Onsi as CFO of combined entity
Monday, 29 Aug 2016 08:51am EDT 

Macrocure Ltd : Leap Therapeutics and Macrocure announce definitive merger agreement . Macrocure Ltd says under terms of agreement, Macrocure will become a wholly owned subsidiary of Leap . Under terms of agreement, Macrocure shareholders will exchange their macrocure shares for newly issued shares of Leap common stock . Combined company is expected to have a minimum of $30 million of cash at closing to finance future operations . Executive team of leap therapeutics will remain in their positions in combined entity . Christopher K. Mirabelli will serve as chief executive officer and chairman of board of directors of combined Co . Equity holders expected to own about 31.8%, and Leap equity holders are expected collectively to own about 68.2%, of combined Co . Says at closing, two macrocure designated individuals, including nissim mashiach, will join Leap's board of directors . Douglas E. Onsi will serve as chief financial officer of combined Co . Existing Leap investors have committed to invest an additional $10 million at closing of transaction . Entities affiliated with healthcare ventures,Eli Lilly, which own all Leap's outstanding voting shares, entered agreements in support of deal . Under terms of agreement, leap will become a public company .Says appointed Douglas E. Onsi, chief financial officer of combined entity.  Full Article

AstraZeneca, Lilly receive FDA fast track designation for AZD3293
Monday, 22 Aug 2016 06:03am EDT 

AstraZeneca Plc :AstraZeneca and Lilly receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer'S disease.  Full Article

Lilly and Astrazeneca receive FDA fast track designation for AZD3293
Monday, 22 Aug 2016 06:00am EDT 

Eli Lilly And Co: Lilly and Astrazeneca receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer's disease .Also announced planned initiation of a second phase 3 trial for azd3293.  Full Article

Lilly-Health Canada approves new indication for Jardiance tablets
Thursday, 11 Aug 2016 07:00am EDT 

Eli Lilly And Co :Health Canada approves new indication for Jardiance (empagliflozin) tablets for adults with type 2 diabetes and established cardiovascular disease.  Full Article

Lilly provides update Abemaciclib trial
Wednesday, 10 Aug 2016 06:45am EDT 

Eli Lilly And Co : Lilly provides update on monarch 2 phase 3 trial of Abemaciclib . "look forward to receiving final monarch 2 results in first half of 2017" . Trial will continue into first half of 2017 . Will await further data and continue to work with FDA to inform its submission plan for single-agent Abemaciclib, based on Monarch 1 study . Says trial will continue into first half of 2017 and will include a final analysis of pfs, overall survival and safety data. .Independent DMC provided recommendation to continue study without modification as interim efficacy criteria were not met.  Full Article

Eli Lilly says got civil investigative demand from U.S. Attorney’s office for southern district of New York
Thursday, 28 Jul 2016 01:48pm EDT 

Eli Lilly : Received a civil investigative demand from the u.s. attorney’s office for southern district of New York - Filing . Civil investigative demand related to documents and information relating to our contracts with, services performed by and payments to pharmacy benefit managers- filing .Eli Lilly says "we are cooperating with this investigation".  Full Article

Eli Lilly says CEO John Lechleiter to retire
Wednesday, 27 Jul 2016 06:45am EDT 

Eli Lilly And Co : On July 27, John Lechleiter announced retirement as president and chief executive officer . Lechleiter will also retire as chairman and a member of board of directors, effective may 31, 2017 .Board elected David Ricks as president and chief executive officer of company.  Full Article

Photo

Trump's corporate tax holiday could spur pharma M&A

U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth.